Abstract
Purpose
Recently, posterior retroperitoneoscopic adrenalectomy (PRA) has been reported to have some advantages over laparoscopic transperitoneal adrenalectomy (LTA). The objectives of this study were to report our experience over 12 years with laparoscopic adrenalectomy for primary hyperaldosteronism (PHA) and to examine surgical outcomes of PRA compared with LTA in patients with PHA.
Methods
The medical records of 527 patients who underwent minimally invasive adrenalectomy, including LTA or PRA, from January 2006 until May 2017 were reviewed at Severance Hospital (Seoul, Korea). Clinicopathologic characteristics and surgical outcomes of 146 patients with PHA who underwent LTA (19 patients) or PRA (127 patients) were analyzed retrospectively by complete chart review.
Results
The overall rates of biochemical and clinical cure were 91.1% and 93.1%, respectively. The mean operation time of the PRA group was significantly shorter than that of the LTA group (72.3 ± 24.1 minutes vs. 115.7 ± 69.7 minutes, P = 0.015). The length of hospital stay in the PRA group was significantly shorter than in the LTA group (3.5 ± 1.3 days vs. 4.2 ± 1.6 days, P = 0.029), and the first meal after surgery came earlier in the PRA group (0.3 ± 0.5 days vs. 0.6 ± 0.5 days, P = 0.049). The number of pain-killers used was also significantly smaller in the PRA group (2.3 ± 2.1 vs. 4.3 ± 2.3, P < 0.001).
Our understanding of primary hyperaldosteronism (PHA), also known as Conn syndrome, has advanced significantly since the first description by Conn approximately 60 years ago [1]. The definition of PHA is a group of disorders involving excessive production of aldosterone, autonomous from the renin-angiotensin system, and nonsuppression by sodium loading [23]. PHA is considered one of the most common causes of secondary hypertension [4]. Several studies have reported that PHA accounts for 1% to 10% of cases of hypertension [456].
PHA can be detected in either a bilateral or unilateral form. If patients are diagnosed with unilateral PHA, the treatment of choice is surgery [78]. Laparoscopic surgery is preferable to open surgery due to better safety, less morbidity, more rapid patient recovery, shorter operative times, and greater cosmesis [910]. The first laparoscopic transperitoneal adrenalectomy (LTA) was performed in 1992, and it has since become the standard treatment for benign adrenal tumors [1112]. However, the transperitoneal approach has some disadvantages, such as risk of visceral damage, ileus after surgery due to bowel manipulation, and CO2 retention, among others [13]. Posterior retroperitoneoscopic adrenalectomy (PRA) is now regarded as a better method for small (less than 7 cm) benign adrenal tumors [14]. A variety of studies have demonstrated that, compared with LTA, PRA has some advantages, including no manipulation of peritoneal organs, direct access to the adrenal gland, shorter operation times, less blood loss, less postoperative pain, and shorter length of hospital stay [1516]. In contrast, the possibility of kidney injury, a smaller working space, and the difficulty of learning the technique are drawbacks to this procedure [17].
In this study, we analyzed cases of laparoscopic adrenalectomy over the last 12 years at our institution. The aims of this study were to describe our 12-year experience with laparoscopic adrenalectomy for PHA and compare surgical outcomes of PRA and LTA in patients with PHA.
We retrospectively reviewed the medical records of 527 patients who underwent minimally invasive adrenalectomy, including LTA or PRA, from January 2006 until May 2017 at Severance Hospital (Seoul, Korea). We excluded patients with a non-functioning tumor (151 patients), Cushing disease (72 patients), pheochromocytoma (84 patients), paraganglioma (45 patients), or a metastatic adrenal mass (29 patients). Clinicopathologic characteristics and surgical outcomes of 146 patients who underwent LTA or PRA with PHA were analyzed by complete retrospective chart review. This study was approved by the local Institutional Review Board, which waived the requirement for informed consent due to the retrospective study design (approval number: 2017-1973-001).
The appropriate timing to assess for PHA remains controversial. The Endocrine Society recommends tests for patients with the following problems [618]: (1) stage 2 of Joint National Commission, systolic/diastolic >160–179/100–109 mmHg; (2) stage 3 of Joint National Commission, systolic/diastolic >180/110 mmHg; (3) spontaneous hypokalemia or diuretic-induced hypokalemia in patients with hypertension; (4) adrenal incidentaloma in patients with hypertension; (5) drug-resistant hypertension; (6) a family history of early onset hypertension; (7) cerebrovascular event at less than 40 years old; and (8) first-degree relatives with PHA. The most common screening test for PHA is the serum aldosterone and plasma renin activity ratio (ARR), which has higher sensitivity and specificity than either aldosterone or plasma renin activity alone [619]. Following an increased ARR over 30 in our institution, the second step for diagnosis of PHA is a confirmatory test, such as oral salt loading, salt infusion test (SIT), fludrocortisone stimulation test, and captopril or losartan challenge test [6]. Of these, our hospital mainly uses SIT. All patients who were screened and underwent confirmatory tests temporarily discontinued their antihypertensive drugs for at least 2 weeks, including diuretics, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, and β-blockers. Mineralocorticoid receptor antagonists were stopped for at least four weeks.
CT is significantly useful for identifying adrenal tumors. However, even though CT has better sensitivity and specificity for finding adrenal tumors than magnetic resonance imaging, the detection rate of CT for small tumors (less than 1 cm in diameter) is only 50% [6]. Lateralization with adrenal venous sampling (AVS) is important for distinguishing unilateral and bilateral PHA and for determining the treatment of choice [20]. The AVS procedure was described in a previous paper [21]. For C-arm CT-assisted AVS, the right femoral vein was accessed under ultrasonographic guidance. After catheterization and venography of the right adrenal vein, 3-dimensional multiplanar reconstruction images by C-arm CT were used to verify proper catheter position. Left AVS was performed without a C-arm CT scan. Blood samples were drawn in the order of right adrenal vein, left adrenal vein, and infrarenal inferior vena cava. The success rate of C-arm CT-assisted AVS is approximately 95% in our institution [22]. The sensitivity and specificity for detection of lateralization are 95% and 100%, respectively [23]. The analysis of AVS lateralization was as follows: (1) if lateralization index (LI) was more than 4, unilateral PHA, (2) if LI was less than 3, bilateral PHA, (3) if LI was over 3 and less than 4, grey zone [24].
Among patients with PHA, adrenalectomy was performed only for unilateral disease identified by diagnostic tests. The surgical procedures for PRA and LTA have been previously described [142526]. For LTA, patients were placed into the lateral decubitus position. Three trocars were usually used for left-side adrenalectomy, and 4 trocars were used for right-side adrenalectomy for liver retraction (Fig. 1) [2526]. For PRA, patients were prepared in the prone position lying on a soft bar below both the anterior and superior iliac spine. The surgical table was tilted with the head downward about 10°. A 1.5-cm skin incision was made just below the lowest tip of the 12th rib. A 1.0-cm port site was made about 4 cm medial from the first skin incision for the camera, and the third 0.5-cm trocar was inserted about 4 cm lateral from the first skin incision along the lowest margin of the 11th rib (Fig. 2). CO2 gas at a pressure of 18 to 20 mmHg was injected to maintain the work space. A 10 mm or 5 mm/30° camera was placed into the medial trocar. To expose the adrenal gland, Gerota's fascia and perinephric fat tissue were delicately dissected. The adrenal vein was ligated with 5-mm clips, and the specimen was removed from the retroperitoneal space using an endoscopic retrieval bag [1425].
All statistical analyses were carried out using IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA). We reported continuous variables as the mean value with standard deviation and categorical variables as numbers with percentages. Comparisons between preoperative and postoperative surgical outcomes were performed using the paired t-test. Chi-square test or Fisher exact test was performed to compare categorical variables between LTA and PRA. A statistically significant difference was defined as P < 0.05.
During the study period, a total of 146 patients were identified as undergoing LTA or PRA for PHA. Table 1 presents baseline clinicopathologic characteristics obtained from the complete chart review. The mean age was 48.3 years (range, 22–81 years). Eighty-five patients (58.2%) were female, and the mean body mass index (BMI) was 24.9 kg/m2 (range, 18.1–41.0 kg/m2). A total of 94 patients (64.4%) underwent AVS examination; among them, 71 patients (75.5%) were diagnosed with successful lateralization, and the LI of 23 patients (24.4%) was less than 4. The mean tumor size was 2.0 cm (range, 0.5–11.7 cm). The majority of patients (134 [91.8%]) underwent laparoscopic surgery, and the rest (12 [8.2%]) were operated on using a robotic system. PRA was performed in 127 patients (87.0%), and the remaining 19 patients (13.0%) underwent LTA. There were 56 patients (38.4%) who underwent right-side surgery, while 90 patients (61.6%) received a left-side operation.
Surgical and clinical outcomes are summarized in Tables 2 and 3. The mean operation time was 78.0 minutes (range, 41–389 minutes), and there were 3 complications, all port-site seromas. The mean length of hospital stay was 3.6 days (range, 2–9 days). The majority of patients (100 [68.5%]) started to eat on the day of surgery, and 41 patients (28.1%) started the day after. The mean number of pain-killers (tridol 50 mg, keromin 30 mg, or pethidine 25 mg) used after surgery was 2.5 injections (range, 0–10 injections). The mean preoperative and postoperative serum ARR were 282.7 (range, 1.12–1,674.4) and 14.2 ng/dL per ng/mL/hr (range, 0.02–100.7 ng/dL per ng/mL/hr), respectively. The number of biochemically cured (defined as ARR < 30 ng/dL per ng/mL/hr and normokalemia without any diuretics in the 6 months after surgery) patients was 133 (91.1%). The preoperative number of antihypertensive drugs used was 2.5 (range, 0–6), and the number used after surgery was 0.9 (0–4). The number of clinically cured patients after surgery was 136 (93.1%); 63 (43.1%) were completely cured (defined as blood pressure less than 140/90 mmHg without the aid of antihypertensive drugs in the 6 months after surgery) and 73 (50.0%) were improved (defined as a reduction of at least one antihypertensive drug in the 6 months after surgery). Ten patients (6.9%) were unable to reduce the number of anti-hypertensive drugs after surgery.
As shown in Table 4, ARR and the number of antihypertensive drugs used were compared between preoperative and postoperative periods. The ARR was significantly lower after surgery (282.7 ± 344.4 ng/dL per ng/mL/hr vs. 14.2 ± 18.1 ng/dL per ng/mL/hr, P < 0.001), and the number of antihypertensive drugs used improved significantly after surgery (2.5 ± 1.2 vs. 0.9 ± 0.9, P < 0.001).
Table 5 compares baseline clinicopathologic characteristics and perioperative outcomes between the PRA and LTA groups. There was no statistically significant difference in age, sex, BMI, tumor size, preoperative ARR, postoperative ARR, or preoperative number of antihypertensive drugs used between the 2 groups.
Left-side surgery was predominant in the LTA group (P = 0.001). The mean operation time for the PRA group was significantly shorter than that of the LTA group (72.3 ± 24.1 minutes vs. 115.7 ± 69.7 minutes, P = 0.015). The length of hospital stay in the PRA group was significantly shorter than in the LTA group (3.5 ± 1.3 days vs. 4.2 ± 1.6 days, P =0.029), and the time to first meal after surgery was also shorter in the PRA group (0.3 ± 0.5 days vs. 0.6 ± 0.5 days, P = 0.049). The number of pain-killers used was significantly fewer in the PRA group (2.3 ± 2.1 vs. 4.3 ± 2.3, P < 0.001). However, the postoperative number of antihypertensive drugs used in the LTA group was significantly fewer than in the PRA group (0.3 ± 0.5 vs. 0.9 ± 0.9, P = 0.011).
PHA has likely been underestimated because of the difficulty of diagnosis without suspicion. ARR is widely used as a screening test for PHA in hypertensive patients. AVS is the gold standard for differentiating between unilateral and bilateral disease. In our institution, C-arm CT-assisted AVS has been performed for lateralization since 2011 [22]. In this study, 92 patients (73.6%) who underwent adrenalectomy after 2011 had an AVS examination. In contrast, only 2 of 21 patients (9.5%) who underwent adrenalectomy before 2011 had an AVS examination. Even though 23 of 94 patients (24.4%) were diagnosed with an LI less than 4, they still underwent adrenalectomy. PHA was suspected because the suppression index (defined as the measure of inhibition of aldosterone secretion in the adrenal gland contralateral to an ipsilateral lesion [24]), which was calculated as the ratio of the cortisol-corrected aldosterone ratio (AC) of the nondominant adrenal gland to the peripheral AC, was less than 1 or clinically unilateral [27].
Cure rate in patients with PHA after adrenalectomy has been reported in the range from 35% to 60% in previous studies [228]. Our cure rate was 43.1% and improved rate was 50%. However, the remaining 10 patients (6.9%) maintained their anti-hypertensive drug use even after surgery, possibly due to a longer hypertension morbidity period or bilateral PHA.
The treatment of choice for unilateral PHA is surgery, minimally invasive adrenalectomy in particular, which is identified as safe; surprisingly, there were only 3 complications of port-site seromas in this study. There are 2 minimally invasive approach methods: LTA and PRA. LTA is the most widely performed method and has some advantages in terms of large working space and a familiar anatomical view. On the other hand, even though PRA is only recommended for small adrenal tumors less than 7 cm, it has many advantages, such as direct exposure of the adrenal gland, no manipulation of adjacent organs, and a relatively shorter operation time.
To compare surgical outcomes between LTA and PRA, we used several perioperative parameters, including operation time, the number of pain-killers used after surgery, length of hospital stay, and time to first meal after surgery. Previous studies report that the mean operation time is shorter for PRA than for LTA [29], and our findings agreed. The requirement for pain-killers was also significantly lower in the PRA group, possibly because of the shorter operation time, small surgical dissection, and need for only three trocars regardless of the side of the operation. The same reasons may have also influenced the length of hospital stay and time to first meal after surgery. However, the only three minor complications occurred in the PRA group; all were port-site seromas that were taken care of by a simple dressing in outpatient care.
We note that there are some limitations to the present study such as its retrospective case-control design and restriction to a single tertiary institution. The LTA group had relatively fewer patients than the PRA group because PRA was predominantly performed for adrenal diseases after 2009 in our institution. In accordance with the patients' hypertension morbidity period, the degree of reduction in postoperative number of antihypertensive drugs used also varied considerably and was not described in a majority of patients' medical records. Furthermore, we excluded perioperative blood pressure and potassium levels, because most patients (85.6%) had taken spironolactone and potassium chloride medication since diagnosis of PHA and underwent adrenalectomy in a normalizing condition of blood pressure and potassium status. Finally, we simply compared the number of pain-killers used between the 2 groups without consideration of dose or type of pain-killer, and pain scores such as visual analog scale were not evaluated after surgery.
In conclusion, PHA is a complex disease from diagnosis to treatment. LTA is still the most widely used surgical approach for unilateral adrenal diseases. In our study, we described the range of disease cure rate through laparoscopic adrenalectomy, with excellent surgical outcomes for the management of PHA using PRA. PRA offers an alternative or likely superior method for treating small adrenal diseases such as PHA, with improved surgical outcomes.
ACKNOWLEDGEMENTS
I would like to thank to all authors who have contributed to this paper.
This study was supported by a faculty research grant of Yonsei University College of Medicine (6-2017-0163).
References
2. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas SA, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med. 1994; 121:877–885.
3. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst. 2001; 2:156–169.
4. Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G. Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol. 2015; 172:R191–R203.
5. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006; 48:2293–2300.
6. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93:3266–3281.
7. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007; 50:911–918.
8. Sywak M, Pasieka JL. Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. Br J Surg. 2002; 89:1587–1593.
9. Sardi A, McKinnon W. Laparoscopic adrenalectomy for primary aldosteronism. JAMA. 1993; 269:989–990.
10. Go H, Takeda M, Takahashi H, Imai T, Tsutsui T, Mizusawa T, et al. Laparoscopic adrenalectomy for primary aldosteronism: a new operative method. J Laparoendosc Surg. 1993; 3:455–459.
11. Gagner M, Lacroix A, Bolte E. Laparoscopic adrenalectomy in Cushing's syndrome and pheochromocytoma. N Engl J Med. 1992; 327:1033.
12. Guazzoni G, Montorsi F, Bocciardi A, Da Pozzo L, Rigatti P, Lanzi R, et al. Transperitoneal laparoscopic versus open adrenalectomy for benign hyperfunctioning adrenal tumors: a comparative study. J Urol. 1995; 153:1597–1600.
13. Fernandez-Cruz L, Saenz A, Benarroch G, Astudillo E, Taura P, Sabater L. Laparoscopic unilateral and bilateral adrenalectomy for Cushing's syndrome. Transperitoneal and retroperitoneal approaches. Ann Surg. 1996; 224:727–734.
14. Walz MK, Peitgen K, Hoermann R, Giebler RM, Mann K, Eigler FW. Posterior retroperitoneoscopy as a new minimally invasive approach for adrenalectomy: results of 30 adrenalectomies in 27 patients. World J Surg. 1996; 20:769–774.
15. Walz MK, Peitgen K, Walz MV, Hoermann R, Saller B, Giebler RM, et al. Posterior retroperitoneoscopic adrenalectomy: lessons learned within five years. World J Surg. 2001; 25:728–734.
16. Walz MK, Gwosdz R, Levin SL, Alesina PF, Suttorp AC, Metz KA, et al. Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasia. World J Surg. 2008; 32:847–853.
17. Rubinstein M, Gill IS, Aron M, Kilciler M, Meraney AM, Finelli A, et al. Prospective, randomized comparison of transperitoneal versus retroperitoneal laparoscopic adrenalectomy. J Urol. 2005; 174:442–445.
18. Chao CT, Wu VC, Kuo CC, Lin YH, Chang CC, Chueh SJ, et al. Diagnosis and management of primary aldosteronism: an updated review. Ann Med. 2013; 45:375–383.
19. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’ screening of hypertensive patients. J Hypertens. 2003; 21:2149–2157.
20. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016; 101:1889–1916.
21. Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics. 2005; 25:Suppl 1. S143–S158.
22. Park SI, Rhee Y, Lim JS, Park S, Kang SW, Lee MS, et al. Right adrenal venography findings correlated with C-arm CT for selection during C-arm CT-assisted adrenal vein sampling in primary aldosteronism. Cardiovasc Intervent Radiol. 2014; 37:1469–1475.
23. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004; 136:1227–1235.
24. Monticone S, Satoh F, Viola A, Fischer E, Vonend O, Bernini G, et al. Aldosterone suppression on contralateral adrenal during adrenal vein sampling does not predict blood pressure response after adrenalectomy. J Clin Endocrinol Metab. 2014; 99:4158–4166.
25. Lee CR, Walz MK, Park S, Park JH, Jeong JS, Lee SH, et al. A comparative study of the transperitoneal and posterior retroperitoneal approaches for laparoscopic adrenalectomy for adrenal tumors. Ann Surg Oncol. 2012; 19:2629–2634.
26. Seo IY, Kye BH, Kim JG, Heo YJ, Cho HM, Park JH, et al. The comparison of laparoscopic adrenalectomy with open adrenalectomy. J Korean Surg Soc. 2006; 70:363–369.
27. Oßwald A, Fischer E, Degenhart C, Quinkler M, Bidlingmaier M, Pallauf A, et al. Lack of influence of somatic mutations on steroid gradients during adrenal vein sampling in aldosterone-producing adenoma patients. Eur J Endocrinol. 2013; 169:657–663.